Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Not yet recruiting 3Unknown 2Recruiting 2Active not recruiting 2Withdrawn 1Terminated 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2Sarcoma 1

Conditions

Breast Neoplasms 2Triple Negative Breast Neoplasms 1Pathologic Complete Response 1Neoplasms 1Hemangiosarcoma 1

Interventions

pembrolizumab 78Fulvestrant 76Carboplatin 74Trastuzumab 71Capecitabine 69Letrozole 62Cyclophosphamide 61Paclitaxel 60pertuzumab 52Specimen Handling 52Docetaxel 50abemaciclib 46ribociclib 44Anastrozole 35130-nm albumin-bound paclitaxel 35trastuzumab deruxtecan 34Magnetic Resonance Spectroscopy 33Blood Specimen Collection 33Tamoxifen 32sacituzumab govitecan 31exemestane 31Biopsy 31Gemcitabine 30Epirubicin 29pyrotinib 28palbociclib 28Surveys and Questionnaires 27Injections 27Drug Therapy 27eribulin 26

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Recruiting × ARX788 × Breast × Clear all
NCT01042379 2026-05-06

I-SPY

QuantumLeap Healthcare Collaborative

Phase 2 Recruiting
5,000 enrolled
BreastSarcoma

Pathologic Complete Response, Breast Neoplasms, Hemangiosarcoma, Neoplasms, Triple Negative Breast Neoplasms

NCT04983121 2022-09-13

Efficacy and Safety of Pyrotinib Maleate Combined With ARX788 Neoadjuvant Treatment in Breast Cancer Patients

Shengjing Hospital

Phase 2 Recruiting
30 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡